Bronchitol Eiropas Savienība - latviešu - EMA (European Medicines Agency)

bronchitol

pharmaxis europe limited - mannitol - cistiskā fibroze - klepus un auksti preparāti - bronchitols ir indicēts cistiskās fibrozes (kf) ārstēšanai pieaugušajiem, kas vecāki par 18 gadiem, kā papildterapiju, lai sasniegtu vislabāko aprūpes līmeni.

Orkambi Eiropas Savienība - latviešu - EMA (European Medicines Agency)

orkambi

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - cistiskā fibroze - other respiratory system products - orkambi tabletes ir indicēts, lai ārstētu cistiskā fibroze (cf) pacientiem vecumā no 6 gadiem un vecākiem, kas ir homozygous par f508del cftr mutācija gēnu. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Colobreathe Eiropas Savienība - latviešu - EMA (European Medicines Agency)

colobreathe

teva b.v. - nātrija kolistimetāts - cistiskā fibroze - antibakteriālas līdzekļi sistēmiskai lietošanai, - colobreathe ir indicēts pseudomonas aeruginosa izraisītu hronisku plaušu infekciju ārstēšanai pacientiem ar cistisko fibrozi (cf), kas vecāki par sešiem gadiem. jāņem vērā oficiālās vadlīnijas par piemērotu izmantot antibakteriālas vielas.

Kalydeco Eiropas Savienība - latviešu - EMA (European Medicines Agency)

kalydeco

vertex pharmaceuticals (ireland) limited - ivacaftor - cistiskā fibroze - other respiratory system products - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 un 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 un 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Symkevi Eiropas Savienība - latviešu - EMA (European Medicines Agency)

symkevi

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cistiskā fibroze - other respiratory system products - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Kaftrio Eiropas Savienība - latviešu - EMA (European Medicines Agency)

kaftrio

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cistiskā fibroze - other respiratory system products - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Mitomycin medac 1 mg/ml pulveris injekciju/infūziju šķīduma pagatavošanai vai intravezikāli lietojama šķīduma pagatavošanai Latvija - latviešu - Zāļu valsts aģentūra

mitomycin medac 1 mg/ml pulveris injekciju/infūziju šķīduma pagatavošanai vai intravezikāli lietojama šķīduma pagatavošanai

medac gesellschaft für klinische spezialpräparate mbh, germany - mitomicīns - pulveris injekciju/infūziju šķīduma pagatavošanai vai intravezikāli lietojama šķīduma pagatavošanai - 1 mg/ml

Balance 1,5% glikoze, 1,25 mmol/l kalcijs, šķīdums peritoneālai dialīzei Latvija - latviešu - Zāļu valsts aģentūra

balance 1,5% glikoze, 1,25 mmol/l kalcijs, šķīdums peritoneālai dialīzei

fresenius medical care deutschland gmbh, germany - kalcija chloridum dihydricum, glikozes monohydricum, magnija chloridum hexahydricum, natrii chloridum, natrii lactatis risinājums - Šķīdums peritoneālai dialīzei

Balance 2,3% glikoze, 1,25 mmol/l kalcijs, šķīdums peritoneālai dialīzei Latvija - latviešu - Zāļu valsts aģentūra

balance 2,3% glikoze, 1,25 mmol/l kalcijs, šķīdums peritoneālai dialīzei

fresenius medical care deutschland gmbh, germany - kalcija chloridum dihydricum, glikozes monohydricum, magnija chloridum hexahydricum, natrii chloridum, natrii lactatis risinājums - Šķīdums peritoneālai dialīzei

Balance 2,3% glikoze, 1,75 mmol/l kalcijs, šķīdums peritoneālai dialīzei Latvija - latviešu - Zāļu valsts aģentūra

balance 2,3% glikoze, 1,75 mmol/l kalcijs, šķīdums peritoneālai dialīzei

fresenius medical care deutschland gmbh, germany - kalcija chloridum dihydricum, glikozes monohydricum, magnija chloridum hexahydricum, natrii chloridum, natrii lactatis risinājums - Šķīdums peritoneālai dialīzei